| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Allovir, Inc. | Chief Medical Officer | Common Stock | 4,030 | $40,605 | $10.08 | 18 Mar 2025 | Direct |
| Kalaris Therapeutics, Inc. | Chief Medical Officer | Stock Option (Right to Buy) | 101,000 | 10 Apr 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| KLRS | Kalaris Therapeutics, Inc. | 10 Apr 2025 | 2 | $0 | 4 | Chief Medical Officer | 11 Apr 2025, 16:52 |
| KLRS | Kalaris Therapeutics, Inc. | 18 Mar 2025 | 2 | $0 | 4 | Chief Medical Officer | 18 Mar 2025, 17:43 |
| KLRS | Kalaris Therapeutics, Inc. | 18 Mar 2025 | 0 | $0 | 3 | Chief Medical Officer | 18 Mar 2025, 17:17 |